Stock Market Today, Feb.: ImmunityBio Surges on Anktiva
Biotech headlines move markets. ImmunityBio, boosted by Anktiva's 700% revenue surge, sparked a rally that may signal...
A snapshot of the year-to-date total market return for 2024, outlining performance drivers and practical implications for investors.
28,420 articlesBiotech headlines move markets. ImmunityBio, boosted by Anktiva's 700% revenue surge, sparked a rally that may signal...
Sweetgreen faced a rough spell as the market punished sweetgreen that once looked unstoppable. Now, smart investors w...
NVIDIA stock investors just received a wave of optimism from analysts who see substantial upside as AI adoption accel...
Utilities are no longer safe havens in 2026 as higher yields and climate liabilities challenge traditional income arg...
Could buying ethereum today spark outsized gains? This article weighs a bank's bold thesis against real-world risks a...
Top multifamily owners don’t wait for year-end reports. They review a concise set of metrics every quarter to steer l...
Two popular aerospace ETFs, XAR and ITA, offer different paths to exposure in a sector shaped by defense spending and...
A big investor just bought millions of Grindr shares after the stock plunged. This article breaks down why grindr sto...
Is there a smarter way to diversify beyond the U.S.? This article explores whether could this international best ETF ...
A mid-cap tech stock has quietly outperformed NVIDIA on a three-year price-return basis, triggering renewed interest ...
A six-year analysis ties CEO ego cues to push for in-person work, highlighting how office-first power dynamics influe...
Salesforce faces a mounting private-equity thesis as cash flow and stock discipline collide with high-profile leaders...